{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-in-pregnancy/background-information/definition/","result":{"pageContext":{"chapter":{"id":"be8adaec-21d7-5658-acb7-9487648799b4","slug":"definition","fullItemName":"Definition","depth":2,"htmlHeader":"<!-- begin field 7156a402-9872-43a6-acba-57b0462e721f --><h2>What is it?</h2><!-- end field 7156a402-9872-43a6-acba-57b0462e721f -->","summary":"","htmlStringContent":"<!-- begin item 85a3600e-7fcb-4128-9f27-81d79524e51b --><!-- begin field efef4822-62a5-4eed-8ad4-15cbaf5613fe --><p><strong>The National Institute for Health and Care Excellence (NICE) defines the different hypertensive disorders of pregnancy as </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019c</a>]<strong>:</strong></p><ul><li><strong>Hypertension:</strong> diastolic blood pressure of 90–109 mmHg and/or systolic blood pressure of 140–159 mmHg. A diastolic blood pressure of 90 mmHg or greater on two occasions more than 4 hours apart, <em>and/or a</em> single diastolic blood pressure reading greater than 110 mmHg should prompt increased surveillance.</li><li><strong>Severe hypertension:</strong> diastolic blood pressure of 110 mmHg or greater and/or systolic blood pressure of 160 mmHg or greater. Systolic blood pressure above 160 mmHg on two consecutive readings at least 4 hours apart should prompt consideration of treatment.</li><li><strong>Chronic hypertension</strong><ul><li>Hypertension that is present at, or prior to the booking visit, or before 20 weeks' gestation. As blood pressure tends to fall during the first and second trimesters, a woman with a high blood pressure before 20 weeks' gestation can be assumed to have pre-existing hypertension.</li></ul></li><li><strong>Gestational hypertension</strong><ul><li>New hypertension presenting after 20 weeks' gestation without significant proteinuria.</li></ul></li><li><strong>Pre-eclampsia</strong><ul><li><strong>New onset of hypertension (over 140 mmHg systolic or over 90 mmHg diastolic) after 20 weeks of pregnancy <em>and </em>the coexistence of 1 or more of the following new-onset conditions:</strong><ul><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/management/pre-eclampsia/#management\">Proteinuria</a></strong></li><li><strong>Other maternal organ dysfunction:</strong><ul><li><strong>Renal insufficiency </strong>(creatinine 90 micromol/litre or more, 1.02 mg/100 ml or more).</li><li><strong>Liver involvement </strong>(elevated transaminases [alanine aminotransferase or aspartate aminotransferase over 40 IU/litre] with or without right upper quadrant or epigastric abdominal pain).</li><li><strong>Neurological complications</strong> such as eclampsia, altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata.</li><li><strong>Haematological complications</strong> such as thrombocytopenia (platelet count below 150,000/microlitre), disseminated intravascular coagulation or haemolysis</li><li><strong>Uteroplacental dysfunction</strong> such as fetal growth restriction, abnormal umbilical artery doppler waveform analysis, or stillbirth.</li></ul></li></ul></li><li><strong>Symptoms of pre-eclampsia include:</strong><ul><li>Severe headaches (increasing frequency unrelieved by regular analgesics).</li><li>Visual problems, such as blurred vision, flashing lights, double vision, or floating spots.</li><li>Persistent new epigastric pain or pain in the right upper quadrant.</li><li>Vomiting.</li><li>Breathlessness.</li><li>Sudden swelling of the face, hands, or feet.</li></ul></li></ul></li><li><strong>HELLP syndrome </strong>(Haemolysis, Elevated Liver enzymes, and Low Platelets syndrome) is a severe form of pre-eclampsia that is associated with high maternal and perinatal morbidity and mortality.</li><li><strong>Eclampsia </strong>is the occurrence of one or more seizures in a woman with pre-eclampsia.</li></ul><p><strong>Additionally, pre-eclampsia can be superimposed on chronic hypertension</strong> — suggested by onset of new symptoms or signs of pre-eclampsia after 20 weeks' gestation in a woman with chronic hypertension [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Duley et al, 2006</a>].</p><!-- end field efef4822-62a5-4eed-8ad4-15cbaf5613fe --><!-- end item 85a3600e-7fcb-4128-9f27-81d79524e51b -->","topic":{"id":"6ecaddc4-ff30-5cf4-ad9e-1df6efa32f1b","topicId":"b42a4357-926e-40db-93be-eb2734585661","topicName":"Hypertension in pregnancy","slug":"hypertension-in-pregnancy","lastRevised":"Last revised in July 2020","chapters":[{"id":"be1a3062-ba16-5320-bc1f-7931438b3b5e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"37d79826-12c0-54a5-859c-f5aab239dccb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ede8737-53eb-57a2-9db3-c67e7b595b36","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"000e1ae9-fec8-5c7e-93fa-aac37cbed3b1","slug":"changes","fullItemName":"Changes"},{"id":"6aee7a8f-5861-5cdc-98a3-6cca34fc56c0","slug":"update","fullItemName":"Update"}]},{"id":"a142cb05-c8c8-5f0b-a31f-aee4193f794a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fb45ed4d-238b-5c83-a4c9-503c743ce614","slug":"goals","fullItemName":"Goals"},{"id":"9fe5bf45-a5b8-5910-9d8c-6c7d392f1779","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"152c0aed-a09e-585e-be86-456cff579be0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e424db7c-6f59-5395-8125-3f64c8335e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"388966c0-e5d0-5421-b48f-b9c11780841e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"aa780aa5-6dd7-53a0-893d-5f60840b81a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c2bcbadf-68d8-5fa9-8752-b5b9846e022a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"be8adaec-21d7-5658-acb7-9487648799b4","slug":"definition","fullItemName":"Definition"},{"id":"a31e2e01-f95d-55d6-a81d-9f251edbf121","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe25ef6b-b112-589a-aa03-6f59c10bb254","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1cacb2e-13ff-5c3f-9767-77524f5938ad","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5a7a190a-9065-5e86-a995-19f480ddc1ae","slug":"complications","fullItemName":"Complications"},{"id":"39c857d6-2892-50eb-926a-0e42813dfdc8","slug":"long-term-health-implications","fullItemName":"Long-term health implications"}]},{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"29858bb6-e45a-5a43-bcf6-707da3b7f93e","slug":"pre-eclampsia","fullItemName":"Scenario: Pre-eclampsia"},{"id":"a7e6503b-bdb3-5f87-8485-0352a165acbf","slug":"pre-existing-hypertension-or-hypertension-before-20-weeks","fullItemName":"Scenario: Pre-existing hypertension, or hypertension before 20 weeks"},{"id":"525f57d9-c730-5acb-bc09-7a9500642f44","slug":"new-hypertension-after-20-weeks","fullItemName":"Scenario: New hypertension after 20 weeks"},{"id":"4fae554e-dd42-5116-9621-ba14519b2cc7","slug":"proteinuria-no-hypertension-after-20-weeks","fullItemName":"Scenario: Proteinuria and no hypertension after 20 weeks"},{"id":"189d666f-8d4d-5259-9194-b51f622a899e","slug":"postpartum-follow-up","fullItemName":"Scenario: Postpartum follow-up"}]},{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d81aa3f7-0ac1-557e-aeb4-85c389e3d449","slug":"aspirin","fullItemName":"Aspirin"},{"id":"9c20faa9-01df-51f3-8ea5-1cff9dc7ba12","slug":"labetalol","fullItemName":"Labetalol"},{"id":"a8bfba7d-aa2a-58dd-8623-f94e9a11868e","slug":"methyldopa","fullItemName":"Methyldopa"},{"id":"80c4cdd6-918d-5b69-9052-a943de729d40","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"be2fc921-a370-593b-83f0-3adf0dbcb226","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4e8e53ad-14b2-51b1-b527-d41b79469ddf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"766ae496-9560-5803-92fa-8d7f71dc073e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0306f0ee-51ab-53f0-bfba-47ceda06c33c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"204ea692-4044-51c2-b0d6-84f596e7ff27","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fe018251-2fcc-5a91-9662-fd930649403a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"961ee437-62d3-5138-83b6-d59d61ff6085","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a96b6bfe-8e8a-51bd-beb4-c719aab1df08","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c2bcbadf-68d8-5fa9-8752-b5b9846e022a","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}